PT  - JOURNAL ARTICLE
AU  - Siddiq, Mustafa M.
AU  - Chan, Angel T.
AU  - Miorin, Lisa
AU  - Yadaw, Arjun S.
AU  - Beaumont, Kristin G.
AU  - Kehrer, Thomas
AU  - White, Kris M.
AU  - Cupic, Anastasija
AU  - Tolentino, Rosa E.
AU  - Hu, Bin
AU  - Stern, Alan D.
AU  - Tavassoly, Iman
AU  - Hansen, Jens
AU  - Martinez, Pedro
AU  - Dubois, Nicole
AU  - Schaniel, Christoph
AU  - Iyengar-Kapuganti, Rupa
AU  - Kukar, Nina
AU  - Giustino, Gennaro
AU  - Sud, Karan
AU  - Nirenberg, Sharon
AU  - Kovatch, Patricia
AU  - Goldfarb, Joseph
AU  - Croft, Lori
AU  - McLaughlin, Maryann A.
AU  - Argulian, Edgar
AU  - Lerakis, Stamatios
AU  - Narula, Jagat
AU  - García-Sastre, Adolfo
AU  - Iyengar, Ravi
TI  - Physiology of cardiomyocyte injury in COVID-19
AID  - 10.1101/2020.11.10.20229294
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.10.20229294
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.10.20229294.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.10.20229294.full
AB  - COVID-19 affects multiple organs. Clinical data from the Mount Sinai Health System shows that substantial numbers of COVID-19 patients without prior heart disease develop cardiac dysfunction. How COVID-19 patients develop cardiac disease is not known. We integrate cell biological and physiological analyses of human cardiomyocytes differentiated from human induced pluripotent stem cells (hiPSCs) infected with SARS-CoV-2 in the presence of interleukins, with clinical findings, to investigate plausible mechanisms of cardiac disease in COVID-19 patients. We infected hiPSC-derived cardiomyocytes, from healthy human subjects, with SARS-CoV-2 in the absence and presence of interleukins. We find that interleukin treatment and infection results in disorganization of myofibrils, extracellular release of troponin-I, and reduced and erratic beating. Although interleukins do not increase the extent, they increase the severity of viral infection of cardiomyocytes resulting in cessation of beating. Clinical data from hospitalized patients from the Mount Sinai Health system show that a significant portion of COVID-19 patients without prior history of heart disease, have elevated troponin and interleukin levels. A substantial subset of these patients showed reduced left ventricular function by echocardiography. Our laboratory observations, combined with the clinical data, indicate that direct effects on cardiomyocytes by interleukins and SARS-CoV-2 infection can underlie the heart disease in COVID-19 patients.One Sentence Summary Cardiomyocytes derived from human induced pluripotent stem cells treated with interleukins and infected with SARS- CoV- 2 in cultures, show increased release of troponin, disorganization of myofibrils, and changes in beating mirroring specific pathologies in some COVID-19 patients.Competing Interest StatementThe A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax and 7Hills Pharma. Adolfo Garcia-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius and Esperovax. Ravi Iyengar has a consulting agreement with Tectonic Therapeutics.Funding StatementThis project was supported in part by the NIH LINCS center grant (U54 HG008098) and by an Icahn School of Medicine at Mount Sinai Pilot Grant for COVID-19 research to R.I. A Centers of Excellence for Influenza Research and Surveillance (CEIRS) (CEIRS, contract # HHSN272201400008C), by NCI grant U54CA260560 and SARS-COV-2 RESEARCH (272201400008C-P00023-9999-2) from NIAID to A.G-S. A.T.C. received funding from the American Heart Association (AHA) 18CDA34080090.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval at Icahn School of Medicine at Mount Sinai, Study-20-01561: Myocardial injury in COVID-19.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or in the supplementary materials.